NovoBliss Research Pvt Ltd
Gandhinagar, Gujarat, India
NCT Number: NCT05800496
This is a randomized, placebo-controlled, double-blind, two-arm, single-centre, proof-of-concept, clinical study to evaluate the safety and efficacy of Plant based Biotin in Healthy Human Subjects with thin, dry, and brittle hair.
a sufficient number (maximum of 54 (27/arm)) of female/male adult subjects were recruited/enrolled to ensure a total of 50 subjects (25 subjects/arm) completed the study.
Looking for future studies?
Notify Me30 year–55 year
All sexes
Interventional
Not applicable
Gandhinagar, Gujarat, India
This is a randomised, placebo-controlled, double-blind, two-arm, single-centre, proof-of-concept, clinical study to evaluate the safety and efficacy of Plant based Biotin in Healthy Human Subjects with thin, dry and brittle hair.
a sufficient number (maximum of 54 (27/arm)) of female/male adult subjects were recruited/enrolled to ensure a total of 50 subjects (25 subjects/arm) completed the study.
total of 51 subjects was completed the study. The potential subjects were screened as per the inclusion & exclusion criteria only after obtaining written informed consent from the subjects. The adult female/male subjects were instructed to visit the facility as per the below visits.
Assessment of efficacy parameters before test treatment usage was done on day 1, and after test treatment usage was done on day 28, and day 56 as listed below.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
mode of usage: 1 capsule in the morning and 1 capsule at night. administration: Oral Administration
Mode of Usage: 1 capsule in the morning and 1 capsule at night. Route of Administration: Oral Administration
Time frame: Day 01,Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To evaluate the effectiveness of test treatment in terms of change in hair density between the treatment and placebo group by using CasaLiteNova (Instrumental Reading)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To evaluate the effectiveness of test treatment in terms of change in hair thickness between the treatment and placebo group by using CasaLiteNova (Instrumental Reading)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To evaluate the effectiveness of test treatment in terms of change in scalp condition between the treatment and placebo group by using CasaLiteNova (Instrumental Reading)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To evaluate the effectiveness of test treatment in terms of reducing facial wrinkle between the treatment and placebo group by using VisioScan (Instrumental Readings)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To evaluate the effectiveness of test treatment in terms of reducing fine lines between the treatment and placebo group by using VisioScan (Instrumental Readings)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in Physician Global Assessment (PGA) between the treatment and placebo group by using Griffiths Scale 0 point= No appearance, 7-9point= Severe
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in Glogau Skin Age between the treatment and placebo group by using Glogau Skin Age Classification
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in skin colour between the treatment and placebo group i.e.L* a* b* and ITA (Individual Topology Angle) using Skin-Colorimeter CL 400 (Instrumental Readings)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in skin elasticity between the treatment and placebo group by using DermaLab Combo (Instrumental Reading)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in skin hydration between the treatment and placebo group by using MoistureMeterEpiD (Instrumental Reading) the result indicated in %
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in Skin Barrier Function between the treatment and placebo group by using Vapometer (Instrumental Reading) the result indicated in %
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in serum ferritin between the treatment and placebo group
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of change in brittle nails between the treatment and placebo group by using Physician Global Assessment (PGA) 0=None, 5= Severe
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of noticeable improvement in Facial Wrinkle between the treatment and placebo group by using Digital Camera (Visual Change)
Time frame: Day 01, Day 28 (+ 02 Days) and Day 56 (+ 02 Days)
To assess the effectiveness of test treatment in terms of Subjective perception on color, fragrance, taste, skin hydration, skin tone, firmness, appearance, hair and nails strongness and shine between the treatment and placebo group by using 9 point Hedonic scale
NovoBliss Research Pvt Ltd
Other
A Proof-of-Concept, Placebo-Controlled, Safety, and Efficacy Study of Plant Based Biotin in Healthy Adult Human Subjects With Thin, Dry, and Brittle Hair
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07271212
Alopecia, Hair Condition
Taichung, Taiwan
View Trial DetailsNCT07500623
Alopecia, Hair Diseases
Broomall, Pennsylvania, United States
View Trial DetailsNCT06605768
Alopecia, Hair Diseases
Kyiv, Ukraine
View Trial DetailsNCT06376409
Alopecia, Hair Diseases
Sacramento, California, United States
View Trial Details